Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Genetic variants in RUNX3 and risk of bladder cancer: a haplotype-based analysis

Genetic variants in RUNX3 and risk of bladder cancer: a haplotype-based analysis Transforming growth factor- (TGF-) is a multifunctional growth factor that plays important roles in many biological processes, whereas RUNX3 is a target of TGF--mediated tumor suppressor pathway. In humans, RUNX3 inactivation may lead to the cancer development, including bladder cancer. To determine whether the RUNX3 polymorphisms are associated with risk of bladder cancer, we conducted a casecontrol study of 368 bladder cancer patients and 368 cancer-free controls to assess the associations between the RUNX3 tagging single-nucleotide polymorphisms (tSNPs) and bladder cancer risk. In the single-locus analysis, we found a significantly increased risk of bladder cancer associated with the SNP7 rs760805 AA genotype (adjusted odds ratio 1.97, 95% confidence interval 1.442.69), compared with the AT/TT genotype. Haplotype-based association analysis revealed that the increased risk of bladder cancer was significantly associated with two haplotypes TATCCCAAAA (2.37, 1.164.83) and AGCTTGAGAG (2.70, 1.086.72) that included the rs760805 A allele. Multifactor dimensionality reduction (MDR) analysis identified a significant more than multiplicative interaction between the SNP7 rs760805 AA and smoking and an additive interaction between the SNP3 rs11249206 TT and smoking on bladder cancer risk. The SNP3 rs11249206, SNP5 rs1395621, SNP7 rs760805, SNP8 rs2236852 and the trichotomized cumulative smoking were the five factors best predicted by the MDR models. When the variables were combined and dichotomized and fitted into the MDR model, the subjects carrying the combined risk stratum had a significantly increased risk for bladder cancer (6.37, 4.578.87, P7.031028). These results suggested that the genetic variants in RUNX3 may modulate the risk of bladder cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Carcinogenesis Oxford University Press

Genetic variants in RUNX3 and risk of bladder cancer: a haplotype-based analysis

Loading next page...
 
/lp/oxford-university-press/genetic-variants-in-runx3-and-risk-of-bladder-cancer-a-haplotype-based-SV1p0P7XcS

References (42)

Publisher
Oxford University Press
Copyright
The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
ISSN
0143-3334
eISSN
1460-2180
DOI
10.1093/carcin/bgn183
pmid
18684727
Publisher site
See Article on Publisher Site

Abstract

Transforming growth factor- (TGF-) is a multifunctional growth factor that plays important roles in many biological processes, whereas RUNX3 is a target of TGF--mediated tumor suppressor pathway. In humans, RUNX3 inactivation may lead to the cancer development, including bladder cancer. To determine whether the RUNX3 polymorphisms are associated with risk of bladder cancer, we conducted a casecontrol study of 368 bladder cancer patients and 368 cancer-free controls to assess the associations between the RUNX3 tagging single-nucleotide polymorphisms (tSNPs) and bladder cancer risk. In the single-locus analysis, we found a significantly increased risk of bladder cancer associated with the SNP7 rs760805 AA genotype (adjusted odds ratio 1.97, 95% confidence interval 1.442.69), compared with the AT/TT genotype. Haplotype-based association analysis revealed that the increased risk of bladder cancer was significantly associated with two haplotypes TATCCCAAAA (2.37, 1.164.83) and AGCTTGAGAG (2.70, 1.086.72) that included the rs760805 A allele. Multifactor dimensionality reduction (MDR) analysis identified a significant more than multiplicative interaction between the SNP7 rs760805 AA and smoking and an additive interaction between the SNP3 rs11249206 TT and smoking on bladder cancer risk. The SNP3 rs11249206, SNP5 rs1395621, SNP7 rs760805, SNP8 rs2236852 and the trichotomized cumulative smoking were the five factors best predicted by the MDR models. When the variables were combined and dichotomized and fitted into the MDR model, the subjects carrying the combined risk stratum had a significantly increased risk for bladder cancer (6.37, 4.578.87, P7.031028). These results suggested that the genetic variants in RUNX3 may modulate the risk of bladder cancer.

Journal

CarcinogenesisOxford University Press

Published: Aug 5, 2008

There are no references for this article.